End Payors Urge 4th Circ. To Revive Celebrex Antitrust Suit

Published: 4/10/2017
End Payors Urge 4th Circ. To Revive Celebrex Antitrust Suit
Source: WWW.LAW360.COM

A potential class of health benefit plans told the Fourth Circuit on Tuesday that they’re allowed to sue Pfizer Inc. over the tactics it allegedly used to get a patent for the inflammation medication Celebrex, as even though they’re indirect purchasers, their states have an exception allowing them to bring antitrust suits.

Read more
Related news
Comment
FACEBOOK